[PMID]: | 28498284 |
[Au] Autor: | Espinosa I; Lee CH; D'Angelo E; Palacios J; Prat J |
[Ad] Endereço: | *Department of Pathology, Hospital de la Santa Creu i Sant Pau, Institute of Biomedical Research (IIB Sant Pau), Autonomous University of Barcelona, Barcelona ‡Department of Pathology, Hospital Ramón y Cajal (IRYCIS), Department of Medicine, University of Alcala, Madrid, Spain †Department of Pathology, Royal Alexandra Hospital, Edmonton, AB, Canada. |
[Ti] Título: | Undifferentiated and Dedifferentiated Endometrial Carcinomas With POLE Exonuclease Domain Mutations Have a Favorable Prognosis. |
[So] Source: | Am J Surg Pathol;41(8):1121-1128, 2017 Aug. |
[Is] ISSN: | 1532-0979 |
[Cp] País de publicação: | United States |
[La] Idioma: | eng |
[Ab] Resumo: | POLE exonuclease domain mutations have recently been described in undifferentiated endometrial carcinoma but, because of the rarity of this aggressive type of endometrial cancer, their prognostic significance is unknown. We have analyzed the immunophenotype (ARID1A, MLH1, PMS2, MSH2, MSH6, p53, ß-catenin, and SMARCB1) and mutational status (POLE, PIK3CA, and PTEN) of 21 undifferentiated carcinomas (8 undifferentiated and 13 dedifferentiated carcinomas). Loss of ARID1A expression was observed in 9 of 19 cases (47%), loss of expression of at least 1 DNA mismatch repair protein in 7 (7/21; 33%), and p53 immunoreaction was aberrant (mutated/inactivated) in 11 cases (11/21; 52%). All tumors were negative for ß-catenin. Normal nuclear SMARCB1 (INI1) staining was found in all but 1 dedifferentiated case. Two undifferentiated and 7 dedifferentiated carcinomas showed POLE exonuclease domain mutations (9/21; 42%). PIK3CA mutations occurred in six tumors (6/21; 28%) (2 undifferentiated and 4 dedifferentiated carcinomas). PTEN mutations were found in 7 of 15 cases (47%) (4 undifferentiated and 3 dedifferentiated carcinomas). POLE-mutated undifferentiated and dedifferentiated endometrial carcinomas were more frequently stage I tumors than similar carcinomas lacking exonuclease domain mutations (7/9; 78% vs. 3/12; 25%; P=0.023) and patients had significantly better outcome (disease-specific survival) than those without POLE exonuclease domain mutations (P=0.02). Determination of the POLE mutation status is important for the management of these patients. |
[Mh] Termos MeSH primário: |
Carcinoma/genética Carcinoma/patologia Desdiferenciação Celular DNA Polimerase II/genética Neoplasias do Endométrio/genética Neoplasias do Endométrio/patologia Mutação
|
[Mh] Termos MeSH secundário: |
Adulto Idoso Exonucleases Feminino Seres Humanos Meia-Idade Proteínas de Ligação a Poli-ADP-Ribose Prognóstico
|
[Pt] Tipo de publicação: | JOURNAL ARTICLE |
[Nm] Nome de substância:
| 0 (Poly-ADP-Ribose Binding Proteins); EC 2.7.7.- (DNA Polymerase II); EC 2.7.7.7 (POLE protein, human); EC 3.1.- (Exonucleases) |
[Em] Mês de entrada: | 1709 |
[Cu] Atualização por classe: | 171116 |
[Lr] Data última revisão:
| 171116 |
[Sb] Subgrupo de revista: | IM |
[Da] Data de entrada para processamento: | 170513 |
[St] Status: | MEDLINE |
[do] DOI: | 10.1097/PAS.0000000000000873 |
|
|